New drug combo aims to control aggressive cancer triggered by chemotherapy
NCT ID NCT05379166
Summary
This study is testing whether combining two drugs, venetoclax and azacitidine, works better than standard care for patients with therapy-related myelodysplastic syndrome (t-MDS). t-MDS is a serious bone marrow disorder that can develop after a person receives chemotherapy or radiation for a previous cancer. The trial will enroll 33 adults to see if this combination can put the disease into remission, improve blood counts, and is safe to use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.